Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Johnson & JohnsonNYSE: JNJ

Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Free cash flow dips below year-ago levels

Q3 FY2026 free cash flow of $6.36B fell 24.1% year over year, behind the +7.9% change in trailing-twelve-month free cash flow. Sequentially, it fell 12.8% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Free cash flow amounted to 20.9% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Free cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -24.1% toward the trailing-twelve-month pace of +7.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$6.36B-12.8% QoQ
Last fiscal yearDec 2025
$19.7B-0.7% YoY
LTMSep 2026
$20.59B+7.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.1%——
1 year-0.7%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
19.7B USD
Year-over-year change
-0.7%
4-year CAGR
-0.1%

Free Cash Flow vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.9% is the 5th highest of 11, against a peer median of -1.4%.
  • Free cash flow amounts to 20.7% of revenue for JNJ, versus a peer median of 24.1%.
JNJ Competitors
Free Cash Flow for JNJ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$20.59B USD+7.9%+4.7%20.7%
ABBVAbbVie Inc.LTM Jun 2026$18.21B USD-0.2%-9.8%28.3%
MRKMerck & Co., Inc.LTM Jun 2026$16.06B USD+9.1%-5.6%24.2%
NVSNovartis AGLTM Jun 2026$15.82B USD-5.9%+13.8%28.4%
GILDGilead Sciences, Inc.LTM Jun 2026$13.2B USD+40.9%+4.3%43.3%
SNYSanofiLTM Jun 2026€11.77B EUR+462.3%+6.4%24.1%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$11.44B USD-21.5%+2.4%23.3%
PFEPfizer Inc.LTM Jun 2026$10.99B USD-11.7%-29.6%17.2%
AMGNAmgen Inc.LTM Jun 2026$10.18B USD-4.1%-2.7%26.7%
AZNAstraZeneca PLCLTM Sep 2026$9.32B USD-2.6%+6.2%15.0%
GSKGSK plcLTM Jun 2026£6.98B GBP+49.6%-4.8%21.0%
Peer median (excluding JNJ) —-1.4%-0.1%24.1%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income20.88B17.94B13.33B14.07B26.8B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
Deferred Income Tax(2.08B)(1.66B)(4.19B)(2.18B)1.54B
Stock-Based Compensation1.14B1.14B1.16B1.18B1.35B
Change in Working Capital(4.24B)(4.01B)2.51B1.84B(12.72B)
Accounts Receivables(2.4B)(1.29B)(624M)(406M)(1.78B)
Inventory(1.25B)(2.53B)(1.32B)(1.13B)(1.45B)
Accounts Payables2.44B1.1B2.35B1.62B2.38B
Other Working Capital(3.03B)(1.29B)2.11B1.75B(11.86B)
Other Non-Cash Items324M819M2.5B2.03B49M
Operating Cash Flow23.41B21.19B22.79B24.27B24.53B
Capital Expenditures(3.65B)(4.01B)(4.54B)(4.42B)(4.83B)
Acquisitions (Net)(60M)(17.65B)358M(15.15B)(17.54B)
Purchases of Investments(30.39B)(32.38B)(10.91B)(1.73B)(920M)
Sales of Investments25.01B41.61B19.39B2.46B1.66B
Other Investing Activities417M65M(3.42B)235M(1.96B)
Investing Cash Flow(8.68B)(12.37B)878M(18.6B)(23.59B)
Debt Repayment(990M)7.45B(2.73B)10.05B9.64B
Common Stock Issued004.24B00
Common Stock Repurchased(3.46B)(6.04B)(5.05B)(2.43B)(5.95B)
Dividends Paid(11.03B)(11.68B)(11.77B)(11.82B)(12.38B)
Other Financing Activities1.43B1.39B(508M)1.07B3.16B
Financing Cash Flow(14.05B)(8.87B)(15.83B)(3.13B)(5.54B)
Effect of Forex Changes(178M)(312M)(112M)(289M)201M
Net Change in Cash502M(360M)7.73B2.25B(4.4B)
Free Cash Flow19.76B17.19B18.25B19.84B19.7B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.